| Vaccines for established cancer: overcoming the challenges posed by immune evasion SH van der Burg, R Arens, F Ossendorp, T van Hall, CJM Melief Nature Reviews Cancer 16 (4), 219-233, 2016 | 711 | 2016 |
| Therapeutic cancer vaccines CJM Melief, T van Hall, R Arens, F Ossendorp, SH van der Burg The Journal of clinical investigation 125 (9), 3401-3412, 2015 | 654 | 2015 |
| The urgent need to recover MHC class I in cancers for effective immunotherapy F Garrido, N Aptsiauri, EM Doorduijn, AMG Lora, T Van Hall Current opinion in immunology 39, 44-51, 2016 | 624 | 2016 |
| Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein JP Medema, J de Jong, T van Hall, CJM Melief, R Offringa The Journal of experimental medicine 190 (7), 1033-1038, 1999 | 427 | 1999 |
| The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes F Dammeijer, M van Gulijk, EE Mulder, M Lukkes, L Klaase, ... Cancer cell 38 (5), 685-700. e8, 2020 | 369 | 2020 |
| M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells M Heusinkveld, PJ de Vos van Steenwijk, R Goedemans, ... The Journal of Immunology 187 (3), 1157-1165, 2011 | 369 | 2011 |
| DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells M Carlsten, NK Björkström, H Norell, Y Bryceson, T van Hall, ... Cancer research 67 (3), 1317-1325, 2007 | 309 | 2007 |
| NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines N van Montfoort, L Borst, MJ Korrer, M Sluijter, KA Marijt, SJ Santegoets, ... Cell 175 (7), 1744-1755. e15, 2018 | 285 | 2018 |
| Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes MPM Vierboom, HW Nijman, R Offringa, EIH Voort, T Hall, L Broek, ... The Journal of experimental medicine 186 (5), 695-704, 1997 | 268 | 1997 |
| Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy MF Fransen, M Schoonderwoerd, P Knopf, MGM Camps, LJAC Hawinkels, ... JCI insight 3 (23), 2018 | 263 | 2018 |
| HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes M Gooden, M Lampen, ES Jordanova, N Leffers, JB Trimbos, ... Proceedings of the National Academy of Sciences 108 (26), 10656-10661, 2011 | 243 | 2011 |
| Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T‐cell activation RA Rosalia, ED Quakkelaar, A Redeker, S Khan, M Camps, JW Drijfhout, ... European journal of immunology 43 (10), 2554-2565, 2013 | 239 | 2013 |
| Monalizumab: inhibiting the novel immune checkpoint NKG2A T Van Hall, P André, A Horowitz, DF Ruan, L Borst, R Zerbib, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 222 | 2019 |
| Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells S Khan, MS Bijker, JJ Weterings, HJ Tanke, GJ Adema, T van Hall, ... Journal of Biological Chemistry 282 (29), 21145-21159, 2007 | 219 | 2007 |
| Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants T van Hall, EZ Wolpert, P van Veelen, S Laban, M van der Veer, ... Nature medicine 12 (4), 417-424, 2006 | 188 | 2006 |
| Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity N van Montfoort, MG Camps, S Khan, DV Filippov, JJ Weterings, ... Proceedings of the National Academy of Sciences 106 (16), 6730-6735, 2009 | 172 | 2009 |
| Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28 T van Hall, A Sijts, M Camps, R Offringa, C Melief, PM Kloetzel, ... The Journal of experimental medicine 192 (4), 483-494, 2000 | 164 | 2000 |
| Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model MWJ Schreurs, AAO Eggert, AJ de Boer, JLM Vissers, T van Hall, ... Cancer Research 60 (24), 6995-7001, 2000 | 163 | 2000 |
| PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy JW Kleinovink, KA Marijt, MJA Schoonderwoerd, T van Hall, F Ossendorp, ... Oncoimmunology 6 (4), e1294299, 2017 | 152 | 2017 |
| Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes JH Kessler, S Khan, U Seifert, S Le Gall, KM Chow, A Paschen, ... Nature immunology 12 (1), 45-53, 2011 | 137 | 2011 |
